Institutions / Abingworth LLP
Abingworth LLP
CIK 1397144 · Institutionalso an insider · as of Dec 31, 2022
Portfolio value
$306.92M
Positions
19
As of
Dec 31, 2022
Portfolio trend
Portfolio value
$306.92M+4.9%Positions
19+0.0%Top holdings
Dec 31, 2022
| Company | Value | % of portfolio |
|---|---|---|
| Vaxcyte, Inc.PCVX | $96.81M | 31.5% |
| Verona Pharma plcRNA | $64.21M | 20.9% |
| Vera Therapeutics, Inc.VERA | $57.28M | 18.7% |
| HilleVax, Inc.HLVX | $30.76M | 10.0% |
| Adicet Bio, Inc.ACET | $18.91M | 6.2% |
| Phathom Pharmaceuticals, Inc.PHAT | $16.10M | 5.2% |
| OnKure Therapeutics, Inc.OKUR | $4.83M | 1.6% |
| Sientra Inc | $3.40M | 1.1% |
| Jasper Therapeutics Inc | $2.72M | 0.9% |
| Soleno Therapeutics IncSLNO | $2.38M | 0.8% |
| Nucana PLC | $2.20M | 0.7% |
| Effector Therapeutics Inc | $2.06M | 0.7% |
| Spruce Biosciences, Inc.SPRB | $1.97M | 0.6% |
| Paratek Pharmaceuticals Inc | $1.95M | 0.6% |
| Cymabay Therapeutics Inc | $821.6K | 0.3% |
| Exicure Inc | $323.9K | 0.1% |
| Aeglea Biotherapeutics Inc | $108.2K | 0.0% |
| Molecular Templates Inc | $66.0K | 0.0% |
| Obseva SA | $12.8K | 0.0% |
Activity
Dec 31, 2022View full history →
InsidersInstitutions
This fund's quarter-over-quarter position changes — what it's buying and selling.| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| Q4 2022 as of | Trim Other (per filing) | Vaxcyte, Inc. common | $-103.08M | -2.1M -51.57% | 2,019,057 31.54% of portfolio | high |
| Q3 2022 as of | Exit Other (per filing) | 82640U107 | $-72.28M | -1.3M -100.00% | 0 | high |
| Q3 2021 as of | New Other (per filing) | 28202V108 | $67.03M | +4.8M | 4,822,114 21.84% of portfolio | high |
| Q3 2021 as of | New Other (per filing) | 471871103 | $58.03M | +5.6M |
Insider transactions
Also trades as an insider
| Date | Action | Company | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|
| May 18, 2021 | Buy Open-market buy | VERA Vera Therapeutics, Inc. Class A Common Stock | $8.50M | +773K +35.32% | 2,960,231 4.11% of shares | high |
| Jan 31, 2022 | Buy Open-market buy | SRRA Sierra Oncology, Inc. Common Stock, $0.001 par value | $4.05M | +150K +12.89% | 1,314,127 | high |
| Jan 28, 2022 | Exercise In-the-money exercise | SRRA Sierra Oncology, Inc. Common Stock, $0.001 par value | $3.79M | +287K +32.79% | 1,164,127 | low |